A preparation method for improving the homogeneity of antibody-drug conjugates and its application
By using transition metal ions in a buffer system to reduce the disulfide bonds between antibody chains and covalently couple them with the drug-linker, the homogeneity problem of antibody-drug conjugates was solved, and efficient and low-cost preparation of D2 conjugates was achieved.
Patent Information
- Application Number
- CN202311769186.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-21
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2043-12-21
AI Technical Summary
Existing technologies make it difficult to prepare highly homogeneous antibody-drug conjugates. Conventional methods result in heterogeneous mixtures, making it difficult to control the number and location of drug-antibody conjugates, which affects the efficacy and safety of the drug.
A novel bioconjugation method was employed to reduce the interchain disulfide bonds of antibodies in a buffer system using transition metal ions, and then covalently couple them with a drug-linker carrying a reactive group to prepare D2 conjugates, thus avoiding modification of the antibody sequence.
It significantly improved the homogeneity of antibody-drug conjugates, with D2 content exceeding 60%, reduced production costs, and simplified the operation process.
Smart Images

Figure CN117838879B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biopharmaceuticals, and in particular relates to a preparation method for improving the homogeneity of an antibody-drug conjugate and an application thereof. Background Art
[0002] ADC (antibody-drug conjugate, antibody-drug conjugate, ADC) contains an antibody for targeting, a linker for drug connection, and a high-efficiency payload (e.g., drug) as an effector. Since the US FDA approved Adcetris (vetuzumab) in 2011, the speed of ADC drugs has gradually increased, and now it has been widely expanded for the treatment of cancer. Currently including Adcetris, Kadcyla (trastuzumab-emtansine conjugate), Besponsa (ointozumab), Mylotarg (gemtuzumab), Polivy (pollotuzumab), Blenrep (mabetuzumab), Enhertu (detrastuzumab), Padcev (ennosumab), Trodelvy (gosartuzumab), Tivdak (teso monoclonal antibody), Zynlonta (lantuximab), Akalux, Lumoxiti (pamozumab) or drugs such as edici. At the same time, more drugs are in the clinical research process.
[0003] Both Kadcyla and Enhertu use trastuzumab, but use DM1 (Mertansine DM1) and DXD (DNA topoisomerase I inhibitor) as payloads, respectively, and their DAR values (drug-to-antibody ratio) are 3.5 and 8, respectively. This shows that the choice of DAR value should be adapted to the type of payload. Among the marketed drugs, Zynlonta (lantuzumab) is a special case. It uses the small molecule drug PBD (pyrrolobenzodiazepine PBD Dimer has the highest toxicity among all ADC payloads. Correspondingly, it has the lowest drug-antibody ratio of 2:1 among the currently marketed ADCs. The design of this drug shows that an important parameter to consider in the selection of DAR value is the toxicity of the payload. The higher the toxicity, the lower the DAR value should be to avoid unnecessary damage to the human body when the payload is released nonspecifically.
[0004] There is no absolute standard for the high and low DAR values in the industry, but it fluctuates within a certain range. Take the ADC with Exatecan (exatecan mesylate) analog as an example. Exatecan analog is a less toxic load, with a DAR value of 8 in Enhertu; but the DAR value in SHR-A1811 is 5.7. Their DAR values are all higher than 4.0 (this is the common DAR value of the toxic load MMAE (monomethyl auristatin E)), but their DAR value difference is as high as 2.3. Therefore, in the process of ADC research and development, trying multiple DAR values is a must.
[0005] For the average DAR value, the differences brought about by the distribution of DAR values also need to be considered. For example, the same ADC with a DAR value of 2, the product obtained by mixing 75% of non-toxic antibodies without drugs and 25% of highly toxic ADC with a DAR value of 8; and the pure ADC with a DAR value of 2, its performance in the organism is different. Because when the dosage of these two groups is low, the substances actually involved in the toxicity comparison are ADC with DAR2 and 1 / 4 of the amount of ADC with DAR8. Therefore, in the process of trying multiple DAR values, ADCs with DAR values that are as specific as possible should be tried to ensure that the results of pharmacological experiments are more valuable for reference.
[0006] In order to meet this demand, a variety of coupling technologies have been developed in order to better prepare ADCs with better homogeneity. For drug connection, functional groups with high reactivity and stability are used for coupling to form stable covalent bonds for both antibodies and linkers-payloads (i.e., linkers-drugs). Conventional connection methods, i.e., covalent bonding of drug moieties to antibodies via linkers, generally result in heterogeneous molecular mixtures, wherein drug moieties are connected to several sites of antibodies. For example, cytotoxic drugs have typically been conjugated to antibodies through multiple lysine residues generally contained in antibodies, producing heterogeneous antibody-drug conjugate mixtures.
[0007] For example, antibody-drug conjugates are usually produced by two conventional chemical strategies: lysine (Lys)-based conjugation and cysteine-based conjugation, which comes from the reduction of interchain disulfide bonds (SS bonds). For the reaction of primary amine groups on lysine residues, the most widely used reactive group on the linker-payload is NHS ester (i.e., N-hydroxysuccinimide). However, the application of NHS esters in the production of antibody-drug conjugates is limited by its inherent properties, such as the reaction between NHS esters and primary amines is very slow under acidic conditions, so conjugation needs to be carried out in a buffer solution with a high pH value (i.e., >7.0), but high pH values are sometimes unfriendly for antibodies, and NHS tends to hydrolyze under alkaline conditions, which makes the purification and identification of free drugs after conjugation more complicated. In addition, due to the low reactivity of NHS esters with primary amines on antibodies, the reaction needs to be carried out at high temperatures (i.e., 22°C). In addition, due to the low solubility, the linker-payload prepared by NHS ester (i.e., SMCC-DM1) requires more organic solvent to be completely dissolved in the reaction system, which increases the risk of antibody aggregation.
[0008] For the conjugation of cysteine from the reduction of interchain disulfide bonds, it includes a step of opening the interchain disulfide bonds in the presence of various reducing agents (such as TCEP (tris (2-carboxyethyl) phosphine), DTT (dithiothreitol) and the like), followed by a nucleophilic reaction of the sulfhydryl groups. In this conjugation process, the antibody-drug conjugate is typically formed as follows: one or more antibody cysteine sulfhydryl groups are conjugated to one or more drug-bound linker moieties, thereby forming an antibody-linker-drug complex. Unlike most amines (which are protonated near pH 7 and have low nucleophilicity), cysteine sulfhydryl groups are reactive at neutral pH. Since free sulfhydryl (RSH, sulfhydryl) groups are relatively reactive, proteins with cysteine often exist in their oxidized form as disulfide-linked oligomers or have internally bridged disulfide bonds. Compared with antibody amines or hydroxyls, antibody cysteine sulfhydryl groups are generally more reactive, i.e., more nucleophilic, to electrophilic conjugation reagents. However, there may be problems with the modification of cysteine sulfhydryl groups by mutating multiple amino acid residues of proteins to cysteine. In concentrated protein solutions, whether in the periplasm of E. coli, culture supernatant, or partially or completely purified proteins, unpaired Cys residues on the protein surface can be paired and oxidized to form intermolecular disulfide bonds, and thus can form protein dimers or polymeric forms. Disulfide dimer formation makes the new Cys unresponsive to conjugation with drugs, ligands or other labels. In addition, if the protein is oxidized to form intramolecular disulfide bonds between the newly modified Cys and the existing Cys residues, both Cys groups cannot be used for active site participation and interaction. In addition, by misfolding or losing the tertiary structure, it is possible to lose protein or become non-specific protein.
[0009] Therefore, it is very important to develop new ADCs as therapeutic agents. However, conventional conjugation methods always result in heterogeneous molecular mixtures in which the drug moiety is connected to several sites on the antibody. Under different reaction conditions, the heterogeneous mixture generally contains antibody distributions with drug moieties connected from 0 to about 8 or more. In addition, in each conjugate subclass with a specific integer ratio of drug moiety / single antibody, there is a potential heterogeneous mixture in which the drug moiety is connected to each site of the antibody. Analysis and preparation methods are not enough to separate and characterize the antibody-drug conjugate species in the heterogeneous mixture obtained by the conjugation reaction. The promotion of heterogeneous mixtures is so complicated that characterization and purification are difficult and expensive. Each conjugated product in such a mixture may have different pharmacokinetics, distribution, toxicity and efficacy curves, and non-specific conjugation often affects the function of the antibody. Antibody is a large, complex and structurally diverse biomolecule with many reactive functional groups. The reactivity of antibodies with linker reagents and drug-linker intermediates depends on factors such as pH, concentration, salt concentration and cosolvent. Furthermore, the reproducibility of multi-step conjugation methods is difficult to ensure due to the difficulty in controlling reaction conditions and characterizing reactants and intermediates.
[0010] Controlling the number of drugs coupled to a single antibody molecule is an important factor in the efficacy and safety of the ADC obtained. For example, in a conjugation method based on the reduction of natural interchain disulfide bonds, the interchain SS bond is more accessible to the solvent than other disulfide bonds. Therefore, the interchain disulfide bond can be used as a binding site for drug (or drug-linker) to be coupled to an antibody. Typically, a therapeutic antibody molecule belonging to an IgG1 or IgG4 subclass has 4 interchain SS bonds, each SS bond is formed by two-SH groups (sulfhydryl groups), so the number of drugs coupled to a single antibody molecule is 2, 4, 6 or 8. If the number of drugs coupled to a single antibody molecule is 0, the product is referred to as D0. Therefore, D2 refers to an ADC coupled to a single antibody molecule by two drug molecules, wherein the two drug molecules can be coupled to-SH groups produced by reducing the SS bonds between the heavy chain and the light chain, or can be coupled to-SH groups produced by reducing the SS bonds between the heavy chain and the heavy chain. D4 refers to an ADC coupled to a single antibody molecule by four drug molecules. D6 refers to an ADC in which six drug molecules are coupled to one single antibody molecule. And D8 refers to an ADC in which eight drug molecules are coupled to one single antibody molecule, i.e., all four interchain SS bonds in one antibody molecule are reduced to eight -SH groups and each -SH group is linked to one drug molecule.
[0011] Typically, the heterogeneous mixture of ADC molecules produced by conventional conjugation methods is a mixture of D0, D2, D4, D6 and D8. It is well known in the art that heterogeneous ADC products are generally unstable and have high immunogenicity. For optimizing efficacy and ensuring constant between doses, it is very important to ensure that the number of conjugated drug moieties of each antibody is the same and that each moiety is specifically conjugated to the same amino acid residue in each antibody. Therefore, methods have been developed to improve the homogeneity of antibody-drug conjugates. Among them, the scheme for selectively preparing D4 and D2 has been studied more extensively.
[0012] The technology of selective preparation of D4 is, for example, the sulfur bridge scheme. Antibody molecules of the IgG1 or IgG4 subclass have four interchain SS bonds. In the sulfur bridge scheme, the four SS bonds are completely reduced, and the linker in the drug-linker will react with two sulfhydryl groups at the same time. Therefore, when the drug-linker reaction is optimized to reach the ideal state, the product of its full reaction with the completely reduced antibody molecule is the D4 product. Since the bridging molecule is a design concept, as long as the molecule has two active sites that can react with sulfhydryl groups, we can understand it as a bridging molecule.
[0013] Patent WO2016064749A2 discloses a linker based on dibromomaleimide, which uses two bromine atoms to replace the two hydrogen atoms on the traditional maleimide. In terms of reaction mechanism, the reaction between maleimide and thiol is an addition reaction, while the reaction between dibromomaleimide and thiol is an addition-elimination reaction, which can occur twice. In terms of the reaction results, it is equivalent to a substitution reaction of thiol to bromine occurring once in each reaction.
[0014] The current reaction site of the bridging molecule is the thiol group, and its reaction mode is similar to that of the traditional linker. From the perspective of mechanism, it is generally divided into addition, substitution or addition-elimination. The problems of bridging molecules are also relatively uniform: there is a possibility of mismatching during the thiol connection reaction, which is mainly manifested in the possibility of generating more semi-antigenic products; in addition, the target DAR value of this series of molecules is only 4. When the target DAR value changes, the bridging molecule cannot maintain its high selectivity; from the perspective of the reaction process, since the reaction always occurs in steps, the thiol nucleophilic substitution requires the substrate to be electron-deficient, but in the existing linker design, there is often a phenomenon of conjugation between multiple reaction centers and the linker parent, which means that after the first step of the reaction, the activity of the reactants is passivated, which requires other methods to control the reaction to avoid the semi-connection phenomenon of the bridging molecule.
[0015] Patent WO2020164561A1 provides another method for selectively preparing D4, which uses metal ions to lock the two SS bonds in the hinge region of the antibody, so that it cannot be reduced under the action of general reducing agents. Under this action, only two disulfide bonds on an antibody can be opened, releasing four thiol groups, so it can selectively prepare D4 products. Similar to the bridging molecule, although this method can adapt to a variety of different linkers, its target DAR value is limited to 4.
[0016] One of the technologies for selectively preparing D2 is site-specific labeling technology, which has been developed and applied to prepare ADCs for preclinical and clinical studies. For example, an improved antibody-drug conjugate THIOMAB has been developed. TM , which provides site-specific conjugation of drugs to antibodies by replacing cysteine at specific sites. The cysteine modified at the site can be used to conjugate cytotoxic drugs but does not interfere with immune protein folding and assembly or change antigen binding and effector functions. However, site-specific labeling technology involves protein modification and / or enzyme catalysis, and thus has disadvantages such as low antibody expression levels, complex purification and high cost.
[0017] Other techniques for inserting unnatural amino acids into sequences have also been applied to prepare D2 conjugates. The reactions of antibodies with unnatural amino acids inserted are orthogonal to the reactions that natural antibodies can perform. In addition to preparing homogeneous antibody-drug 1:2 conjugates when a total of two unnatural amino acids are inserted into the antibody, conventional reactions can also be used to prepare multi-drug ADCs. Similar to cysteine-edited proteins, unnatural amino acid editing is also limited by low expression levels and complex purification. In addition, it also requires the establishment of a tRNA system for translating unnatural amino acids, which is more expensive and complex than antibodies with cysteine inserted.
[0018] To prepare homogeneous antibody-drug 1:2 conjugates, affinity peptides can also be used to identify regions of antibody sequences and couple the identified regions to achieve homogeneous antibody-drug conjugate preparation. For example, Fc-III affinity peptides with p-benzoylphenyl groups react with methionine under 365nm light; however, the peptides used in affinity peptide technology need to be purified and removed after coupling. Since the molecular weight of peptides is larger than that of general small molecule drugs, their purification is more difficult and expensive.
[0019] Currently, there is a large demand for the research and development and production of D2-type antibody-drug conjugates in the market. However, the current scheme for selective production of D2 has problems such as the need to modify the sequence and the complex and expensive purification process. Therefore, the development of a simple and low-cost scheme for preparing highly homogeneous D2 ADC has important applications in the ADC drug preparation process. Summary of the invention
[0020] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a preparation method and application of antibody-drug conjugates with improved homogeneity. The present invention develops a new bioconjugation method for selectively producing D2, which selectively modifies two drug molecules in the hinge region of the antibody using any given reactive linker without modifying the antibody sequence. The method can produce ADCs with improved homogeneity, and the method is simple to operate and can achieve cost reduction and efficiency improvement.
[0021] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0022] In a first aspect, the present invention provides a method for preparing an antibody-drug conjugate to improve homogeneity, the method comprising:
[0023] (1) incubating a reducing agent and an antibody to be conjugated in a buffer system containing transition metal ions to reduce interchain disulfide bonds within the antibody to generate reduced thiol groups;
[0024] (2) covalently coupling the drug-linker complex carrying two reactive groups to the reduced thiol group obtained in step (1); thereby preparing an antibody-drug conjugate mixture.
[0025] The present invention develops a new bioconjugation method, which can produce ADC with improved homogeneity, and the preparation method is simple to operate, which can achieve the effect of reducing costs and increasing efficiency. The ADC produced by the bioconjugation method of the present invention is highly safe and has better efficacy. The operation process of the present invention is relatively simple, and commercially available products can be used to complete purification under simple operations.
[0026] Specifically, the method of the present invention can significantly improve the homogeneity of antibody-drug conjugates (ADCs) produced by the method compared with conventional conjugation methods using a reducing agent and a nucleophilic reaction of a thiol group. The content of D2 is generally higher than 60%, while the content of D2 in conventional processes is generally lower than 40%.
[0027] In the present invention, the presence of transition metal ions enables selective reduction of disulfide bonds. In the presence of transition metal ions, two interchain SS bonds in the Fab region are selectively reduced. Therefore, two linkers-payloads carrying two reactive groups are connected to one antibody to form D2. The high content of D2 in the obtained ADC undoubtedly improves the homogeneity of ADC.
[0028] Preferably, in step (1), the reducing agent is selected from: tri(2-carboxyethyl)phosphine (TCEP), diphenylphosphinoacetic acid, 2-[2-(diphenylphosphino)ethyl]pyridine, 3-(diphenylphosphino)benzenesulfonic acid, 4-(diphenylphosphino)benzoic acid, 2-(diphenylphosphino)ethylamine, 3-(diphenylphosphino)propylamine, 3-(diphenylphosphino)propionic acid, 2-(diisopropylphosphino)ethylamine, 2-(diphenylphosphino)benzoic acid, (2-hydroxyphenyl)diphenylphosphine, 1,3,5-triaza-7-phosphatricyclo[3.3.1.13.7]decane, n-butyldi(1-adamantyl)phosphine or its salt, sodium triacetoxyborohydride or sodium cyanoborohydride, any one or a combination of at least two thereof.
[0029] Preferably, in step (1), the final concentration of the reducing agent in the incubation system is 0.04-0.4 mM, for example, it can be 0.04 mM, 0.08 mM, 0.1 mM, 0.12 mM, 0.15 mM, 0.2 mM, 0.25 mM, 0.3 mM, 0.35 mM or 0.4 mM, etc.
[0030] Preferably, in step (1), the transition metal ion is selected from: Zn 2+ 、Cd 2+ or Hg 2+ Any one or a combination of at least two.
[0031] Preferably, in step (1), the transition metal ion is added to the buffer system in the form of a transition metal salt, and the transition metal salt is selected from the group consisting of: ZnCl2, Zn(NO3)2, ZnSO4, Zn(CH3COO)2, ZnI2, ZnBr2, Zn(HCOO)2, Zn(BF4)2, CdCl2, Cd(NO3)2, CdSO4, Cd(CH3COO)2, CdI2, CdBr2, Cd(HCOO)2, Cd(BF4)2, HgCl2, Hg(NO3)2, HgSO4, Hg(CH3COO)2, HgBr2, Hg(HCOO)2 or Hg(BF4)2, any one or a combination of at least two thereof.
[0032] In the present invention, transition metal ions suitable for use in the bioconjugation method of the present invention may include but are not limited to Zn 2+ 、Cd 2+ , Hg 2+ Among them, due to Zn 2+ Relatively easy to obtain and low cost, Zn 2+ For example, appropriate transition metal salts may be added in step (1) as long as they are soluble in the reaction solution so that free transition metal ions can be released into the reaction solution.
[0033] In the present invention, Zn 2+ For example, transition metal salts of Cd2, Zn(NO3)2, ZnSO4, Zn(CH3COO)2, ZnI2, ZnBr2, zinc formate or zinc tetrafluoroborate, etc. Similarly, soluble Cd2 can be added to the reaction solution and can release free Cd2. 2+ or Hg 2+ Other transition metal salts of ions may include, but are not limited to: CdCl2, Cd(NO3)2, CdSO4, Cd(CH3COO)2, CdI2, CdBr2, Zn(HCOO)2, Zn(BF4)2, HgCl2, Hg(NO3)2, HgSO4, Hg(CH3COO)2, HgBr2, Hg(HCOO)2 or Hg(BF4)2, etc.
[0034] Preferably, in step (1), the final concentration of the transition metal ion in the incubation system is 0.01-0.2 mM, for example, it can be 0.01 mM, 0.02 mM, 0.04 mM, 0.05 mM, 0.06 mM, 0.08 mM, 0.1 mM, 0.12 mM, 0.14 mM, 0.15 mM, 0.16 mM, 0.18 mM or 0.2 mM, etc.
[0035] In the present invention, transition metal ions are the key factor responsible for the high level of D2 and low levels of D0, D1, D3 and D4 in the obtained ADC.
[0036] Preferably, in step (1), the buffer system is selected from: any one of HEPES buffer, histidine buffer, PBS buffer or MES buffer, or a combination of at least two thereof.
[0037] In the present invention, the buffer solution system needs to have a buffering capacity within a specified pH range, and the corresponding buffer system should not cause precipitation of transition metal ions and should not have a strong chelating effect with transition metal ions.
[0038] Preferably, in step (1), the pH of the buffer system is 5-8, for example, 5, 5.5, 6, 6.5, 7, 7.5 or 8, and preferably 5.5-7.5.
[0039] Preferably, in step (1), the incubation temperature is: -10°C to 37°C, for example, it can be -10°C, -5°C, 0°C, 5°C, 10°C, 15°C, 20°C, 30°C or 37°C, etc., preferably 0 to 20°C.
[0040] Preferably, in step (1), the incubation time is 8-24 hours, for example, 8, 10, 12, 14, 16, 18, 20, 22 or 24 hours.
[0041] Preferably, in step (2), the linker portion of the linker in the complex that is coupled to the antibody contains at least two reactive groups that are covalently coupled to two thiol groups on the antibody, respectively.
[0042] In the present invention, the present invention has no particular restrictions on the antibodies conjugated to the linker-drug using the bioconjugation method. The choice of antibody depends on the disease or condition (e.g., cancer) treated by the antibody-drug conjugate (ADC). The antibody can specifically bind to the corresponding antigen (also called tumor-associated antigen (TAA)), viral antigen or microbial antigen expressed on cancer cells, has antibody-dependent cell-mediated phagocytosis (ADCP) activity, and has in vivo anti-tumor, anti-viral or anti-microbial activity. The interchain SS bond in the antibody is the site for connecting the drug-linker complex.
[0043] In some embodiments, the antibody may include, but is not limited to, a monoclonal antibody or a polyclonal antibody. Specific examples of antibodies include: human antibodies, humanized antibodies, or chimeric antibodies.
[0044] In some embodiments, the antibody is a monoclonal antibody, eg, a human antibody or a humanized antibody.
[0045] Preferably, in step (2), the reactive groups in the complex are selected from: dibromomaleimide, 4,5-dibromo-1,2-dihydro- Any one or a combination of at least two of -3,6-diketone, maleimide, organic bromide, iodide, sulfone compound or alkene or alkyne compound with electron-deficient group.
[0046] In the present invention, for the desired drug and the selected linker, those skilled in the art can select an appropriate method to couple them together. Since the ratio of the drug to the reactive group involved in the present invention is 1:2, the linker part coupled to the antibody molecule in the linker can be a special dual reactive group linker such as dibromomaleimide, etc. Or any combination of conventional linkers. The most common reactive group that can bond to the thiol group in the preparation of ADC is maleimide. In addition, organic bromides, iodides, sulfone compounds, olefins and alkynes with electron-deficient groups are also often used.
[0047] In the present invention, the method has a high tolerance for the type of linkers and can effectively adapt to a variety of different linkers.
[0048] Preferably, in step (2), the drug in the complex has cytotoxic, anti-tumor or labeling effects.
[0049] Preferably, in step (2), the conditions for covalent coupling are: the molar concentration of the drug in the covalent coupling system is at least 2 times or more greater than the antibody concentration, the reaction temperature is -10°C to 37°C, for example, it can be -10°C, -5°C, 0°C, 5°C, 10°C, 15°C, 20°C, 30°C or 37°C, etc., and the reaction time is 0.5-24 hours, for example, it can be 0.5, 1, 6, 12, 18 or 24, etc.
[0050] Preferably, the reaction temperature is 0°C to 20°C.
[0051] Preferably, the covalent coupling system further comprises an organic solvent, and the organic solvent keeps the system clear.
[0052] Preferably, the covalent coupling system further comprises a metal chelator, which regulates the reactivity of the drug.
[0053] Preferably, the metal chelating agent includes any one of EDTA, DPTA or DOTA or a combination of at least two of them.
[0054] Preferably, the concentration of the metal chelator is 0-3 times the concentration of the antibody.
[0055] In the present invention, when covalent coupling is performed, the substance concentration of the drug is at least 2 times or more greater than the antibody concentration; depending on the solubility of the drug, an organic solvent can be added to the reaction system during covalent coupling to keep the system clear; depending on the reactivity of the drug, a metal chelator such as EDTA, DPTA or DOTA, etc., which is 0-3 times the antibody concentration, can be added to the reaction system during covalent coupling to adjust the reactivity of the drug. The specific reaction temperature and time are determined according to the reactivity of the drug, and the reaction temperature is usually -10°C to 37°C, preferably 0°C to 20°C, and the reaction time is usually 0.5-24 hours.
[0056] The present invention has no particular limitations on the drugs and linkers that can be used in the bioconjugation method of the present invention. The drug molecule needs to have the desired effect (e.g., cytotoxicity, anti-tumor or labeling, etc.) and have at least one substituent group or partial structure that allows connection to the linker structure, and the linker part of the linker coupled to the antibody contains at least two reactive groups that are covalently coupled to the two thiol groups on the antibody.
[0057] Various diagnostic agents, therapeutic agents and labeling agents known in the art can be conjugated to antibody molecules. For example, in the broadest sense, the drug to be conjugated can include diagnostic agents, drug molecules, for example, cytotoxic agents, toxins, radionuclides, fluorescent agents. Among them, fluorescent agents, for example, amine-derived fluorescent probes, such as 5-dimethylaminonaphthalene-1-(N-(2-aminoethyl))sulfonamide-dansylethylenediamine, or Oregon 488 cadaverine (catalog number O-10465, Molecular Probes), or dansyl cadaverine, or N-(2-aminoethyl)-4-amino-3,6-dithio-1,8-naphthalene imine, or dipotassium salt (fluorescein ethylenediamine), or rhodamine B ethylenediamine (catalog number L-2424, Molecular Probes), or thiol-derivatized fluorescent probes, such as FLL-Cysteine (Catalog No. B-20340, Molecular Probes).
[0058] Preferably, the method further comprises the step of reoxidizing the unreacted thiol groups in step (2) using an oxidizing agent.
[0059] Preferably, the oxidant is selected from: any one of dehydroascorbic acid, 5,5-dithiobis(2-nitrobenzoic acid), oxygen or air, or a combination of at least two thereof.
[0060] Preferably, in step (3), the final concentration of the oxidant is 0.04-0.8 mM, for example, it can be 0.04 mM, 0.06 mM, 0.08 mM, 0.1 mM, 0.15 mM, 0.2 mM, 0.25 mM, 0.3 mM, 0.35 mM, 0.4 mM, 0.45 mM, 0.5 mM, 0.55 mM, 0.6 mM, 0.65 mM, 0.7 mM, 0.75 mM or 0.8 mM, etc.
[0061] Preferably, in step (3), the reaction conditions of the oxidation are: the concentration of the oxidant is at least higher than the concentration of the antibody, the temperature is: -10°C to 37°C, preferably 0°C to 20°C; and the reaction time is 0.5-24 hours.
[0062] Preferably, step (2) further comprises a purification step, wherein the purification comprises: using EDTA as a chelating agent to remove transition metal ions.
[0063] Preferably, the purification method comprises: purification using any one of a desalting column, size exclusion chromatography, hydrophobic interaction chromatography, an ultrafiltration tube or a tangential flow filtration system or a combination of at least two thereof.
[0064] In the present invention, a purification step is further included after the oxidation step, and the transition metal ions can be removed in the subsequent purification step to reduce the impact on the quality of the final product. Exemplarily, by using EDTA as a chelating agent, the transition metal ions are removed in the purification step, and the chelating agent will be filtered out in the subsequent dialysis, ultrafiltration or gel filtration.
[0065] Preferably, the preparation method comprises:
[0066] (1) Containing Zn 2+ 、Cd 2+ or Hg 2+ A transition metal salt of any one of the transition metal ions in the incubation system is added to the buffer system, wherein the buffer system is selected from any one of HEPES buffer, histidine buffer, PBS buffer or MES buffer or a combination of at least two thereof, and the pH of the buffer system is 5-8; the reducing agent and the antibody to be conjugated are incubated at -10°C to 37°C for 8-24 hours in the buffer system containing the transition metal ion to selectively reduce the intrachain disulfide bonds of the antibody; the final concentration of the reducing agent in the incubation system is 0.04-0.4 mM, and the final concentration of the transition metal ion in the incubation system is 0.01-0.2 mM;
[0067] (2) covalently combining a drug having cytotoxic, anti-tumor or labeling effects with a linker containing at least two reactive groups to obtain a drug-linker complex having two reactive groups; the reactive groups are covalently coupled to two thiol groups on the antibody respectively; covalently coupling an excess of the drug-linker complex having two reactive groups with the reduced thiol groups obtained in step (1); the conditions for the covalent coupling are: the molar concentration of the drug in the covalent coupling system is at least 2 times or more of the antibody concentration, the reaction temperature is -10°C to 37°C, and the reaction time is 0.5-24 hours;
[0068] An oxidant is used to reoxidize unreacted thiol groups, and the final concentration of the oxidant is 0.04-0.8 mM; the reaction conditions of the oxidation are: the concentration of the oxidant is at least higher than the concentration of the antibody, the temperature is: -10°C to 37°C; the reaction time is 0.5-24 hours; and the antibody-drug conjugate is recovered by purifying using any one or a combination of at least two of a desalting column, size exclusion chromatography, hydrophobic interaction chromatography, ultrafiltration tube or tangential flow filtration system.
[0069] In a second aspect, the present invention provides use of the preparation method for improving the homogeneity of an antibody-drug conjugate according to the first aspect in the preparation of an ADC drug.
[0070] The numerical range described in the present invention not only includes the point values listed above, but also includes any point values between the above numerical ranges that are not listed. Due to space limitations and for the sake of simplicity, the present invention no longer exhaustively lists the specific point values included in the range.
[0071] Compared with the prior art, the present invention has the following beneficial effects:
[0072] (1) The present invention can selectively prepare homogeneous antibody-drug 1:2 conjugates, and the present invention successfully proves that transition metal ions are the key factor responsible for the high level of D2 and low levels of D0, D1, D3 and D4 in the obtained ADC. In addition, the present invention also proves that the method produces ADC products with high Fab preference. The method has been confirmed with several commercial therapeutic antibodies and shows great consistency.
[0073] (2) In the present invention, the antibody-drug 1:2 conjugate accounts for more than 60%wt% of the total components of the product. By using the method for producing the antibody-drug conjugate of the present invention, the homogeneity of the antibody-drug conjugate is higher than that of the product produced by the conventional conjugation method. Specifically, in the ADC prepared by the method of the present invention, the content of D0+D4 is less than 20wt%, and the content of D3 is less than 20wt%. In addition, the content of D2 is generally more than 60wt%, and for example more than 70wt%. In the ADC prepared by the conventional conjugation method, the content of D2 is generally less than 40wt%.
[0074] (3) The connection site between the drug and the antibody in the present invention is concentrated on the disulfide bond between the light chain and the heavy chain of the antibody. After the metal complex hinge region is used, it is helpful to reduce the opening of the disulfide bond between the heavy chains. The method of the present invention avoids protein modification or enzyme catalysis, but is based on natural interchain disulfide bonds, only requires transition metal ions, and does not use expensive enzyme catalysts, further reducing costs. Therefore, compared with the conventional method for preparing ADC, the method of the present invention is less complex, simple to operate, and the homogeneity of the obtained antibody-drug conjugate is significantly improved, and the cost is greatly reduced. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 is the HIC of the Herceptin-DBM-MMAF conjugate prepared by the method of the present invention.
[0076] Figure 2 is the HIC of Herceptin-DBM-MMAF conjugate prepared by using conventional methods.
[0077] Figure 3 The LC-MS of the Herceptin-DBM-MMAF conjugate prepared by the method of the present invention after Lys-C digestion.
[0078] Figure 4 LC-MS of Lys-C cleavage of Herceptin-DBM-MMAF conjugate prepared by conventional method.
[0079] Figure 5 is the HIC of the Rituxan-MMAF conjugate prepared by the method of the present invention.
[0080] Figure 6 is a HIC of Rituxan-MMAF conjugate prepared by using conventional methods.
[0081] Figure 7 is the HIC of the Erbitux-MMAF conjugate prepared by the method of the present invention.
[0082] Figure 8 is a HIC of Erbitux-MMAF conjugate prepared by using conventional methods.
[0083] Fig. 9 is the HIC of Herceptin-diBrPD-MMAE conjugate prepared by using the method of the present invention.
[0084] Fig.10 is the HIC of Rituxan-diBrPD-MMAE conjugate prepared by using the method of the present invention.
[0085] Fig.11 is the HIC of Erbitux-diBrPD-MMAE conjugate prepared by using the method of the present invention.
[0086] Fig.12 is the HIC of Herceptin-bismaleimide-MMAE conjugate prepared by using the method of the present invention.
[0087] Fig.13 is the HIC of Rituxan-bismaleimide-MMAE conjugate prepared by using the method of the present invention.
[0088] Fig.14 is the HIC of Erbitux-bismaleimide-MMAE conjugate prepared by using the method of the present invention. DETAILED DESCRIPTION
[0089] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0090] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0091] Example 1 Preparation of Herceptin-DBM-MMAF conjugate and homogeneity testing of the conjugate
[0092] The Herceptin-DBM-MMAF conjugate was prepared by a one-pot reaction, and the specific steps are as follows:
[0093] (1) ZnCl2 (0.12 mM) and TCEP (0.098 mM) were added to a solution of Herceptin (prepared by WuXi Biologics according to the published corresponding protein sequence by a standard method for preparing monoclonal antibodies, 0.03 mM, in phosphate buffer, pH 7, 20 mM) and the reaction mixture was allowed to stand at 4°C overnight.
[0094] (2) DBM-MMAF (commercially available from WuXi Apptec., 0.12 mM) in DMA (dimethylacetamide, commercially available from Aldrich Sigma) was introduced, and the reaction was continued at 4°C for 2 hours.
[0095] (3) N-acetyl cysteine (0.24 mM) was added to deplete excess DBM-MMAF.
[0096] (4) Add EDTA (0.24 mM) to capture Zn 2+ And DHAA (commercially available from Aldrich Sigma, 0.24 mM) was added to oxidize excess thiol groups.
[0097] (5) The reaction mixture was purified using a desalting column (Type: 40K, 0.5 mL, REF: 87766, Lot # SJ251704, Manufacturer: Thermo).
[0098] As a control, the reaction was carried out in the presence of 0.06 mM TCEP but without ZnCl2 by the same procedure.
[0099] Homogeneity was determined. Drug / antibody ratio (DAR) and product distribution were analyzed using HIC-HPLC. Purification of D0, D1, D2, D3 and D4 was performed by hydrophobic interaction chromatography (HIC) on Tosoh TSKgel Butyl-NPR 4.6 mm ID×3.5 cm, 2.5 μm at a flow rate of 0.6 mL / min at ambient temperature. The injection volume was 50 μg, and solvent A was 1.5 M (NH4)2SO4 and 50 mM sodium phosphate pH 7. Solvent B was 75% v / v 50 mM sodium phosphate pH 7 and 25% v / v isopropanol. Different drug-loaded materials were eluted by sequential step gradients. The results of the assay are shown in Tables 1 and Figure 1-2 middle, Figure 1 is the HIC of the Herceptin-DBM-MMAF conjugate prepared by the method of the present invention, Figure 2 is the HIC of Herceptin-DBM-MMAF conjugate prepared by using conventional methods.
[0100] Table 1
[0101]
[0102] As can be seen from Table 1, the two Herceptins prepared by the method of the present invention and the conventional method have very similar HIC DAR values, which means that each antibody in the two products is coupled with nearly two MMAFs on average. Correspondingly, the content of D2 component in the sample synthesized by the method of the present invention is 71.43%, which is significantly higher than 39.32% in the sample of the conventional method. Therefore, the sample synthesized by the method of the present invention can better reflect the characteristics of the D2 component, and the D2 component is an ideal sample. The component with two drugs on each antibody is called the D2 component, so the sample synthesized by the method of the present invention is closer to the ideal. On the other hand, it can be seen that Figure 2 The image ratio of the D2 component Figure 1 Since there are 4 pairs of thiol groups on the antibody for coupling, it is possible to generate multiple isomers coupled at different sites, among which there are 3 isomers with the largest differences, corresponding to Figure 2 There are three small peaks of D2 component that are difficult to separate. Figure 1 The D2 peak in the sample is a single peak, which means that the D2 sample synthesized by the method of the present invention has good site selectivity. To prove this, the binding site was determined in this example.
[0103] Binding site determination was performed. Using HPLC-MS in combination with a Lys-C kit (commercially available from Wako Pure Chemical Industries, Ltd.), 1 μL of Lys-C enzyme (10 units dissolved in distilled water) and 3 μL of 1M Tris buffer (pH=8.0) were added to 15 μg of Herceptin-DBM-MMAF solution prepared by the method of the present invention and the conventional method, respectively. The volume of the solution was then supplemented to 15 μL with ultrapure water, and the solution was incubated at 37°C for 15 minutes before analysis on HPLC-MS (chromatographic column model: Agilent PLRP-S1000A, 8 μm, 50×2.1 mm). The results are shown in Tables 2 and 3. Figure 3-4 middle. Figure 3 is the LC-MS of the Herceptin-DBM-MMAF conjugate prepared by the method of the present invention after Lys-C digestion, Figure 4 LC-MS of Lys-C cleavage of Herceptin-DBM-MMAF conjugate prepared by conventional method.
[0104] Table 2
[0105]
[0106]
[0107] Lys-C enzyme will selectively hydrolyze the intact antibody into two Fab and one Fc, where Fab contains one disulfide bond that can be reduced and Fc contains two disulfide bonds that can be reduced. Figure 3 and Figure 4 The summary of the original data, from the results in Table 2, it can be seen that the Herceptin-DBM-MMAF synthesized by the method of the present invention has its coupling reaction modification sites concentrated in the Fab region of the antibody, and there is no mass spectrometry signal of the coupling compound visible in the Fc region; the reaction is highly specific in terms of location selectivity. However, for Herceptin-DBM-MMAF synthesized only by conventional methods, the drug coupling sites are randomly distributed in the Fc region and Fab region of the antibody. According to the general understanding of antibody-drug conjugate research and development, there are certain differences in the performance of the final drug when the drug is coupled to different sites on the antibody. If samples with specific coupling sites can be used in the early stages of research, it will greatly facilitate the subsequent sample selection. Figure 3 and Figure 4 It can also be seen intuitively that Figure 3 The spectrum has significantly fewer peaks and is more uniform.
[0108] Example 2. Preparation of DBM-MMAF conjugates of other antibodies and homogeneity testing of the conjugates
[0109] In order to prove that the method is applicable to more types of antibodies, this example selected two other commercially available antibodies (Rituxan / Erbitux) for coupling according to the method of the present invention and the conventional method. The selection of antibodies in this example was based solely on the market availability of the antibodies.
[0110] The DBM-MMAF conjugate of the antibody was prepared in a one-pot reaction, and the specific steps are as follows:
[0111] (1) ZnCl2 (0.12 mM) and TCEP (0.098 mM) were sequentially added to a solution of Rituxan / Erbitux (prepared by WuXi Biologics according to the published corresponding protein sequence by a standard method for preparing monoclonal antibodies, 0.03 mM, in phosphate buffer, pH 7, 20 mM) and the reaction mixture was allowed to stand at 4°C overnight.
[0112] (2) DBM-MMAF (commercially available from WuXi Apptec., 0.12 mM) in DMA (commercially available from Aldrich Sigma) was introduced, and the reaction was continued at 4°C for 2 hours.
[0113] (3) N-acetyl cysteine (0.24 mM) was added to deplete excess DBM-MMAF.
[0114] (4) Add EDTA (0.24 mM) to capture Zn 2+ And DHAA (commercially available from Aldrich Sigma, 0.24 mM) was added to oxidize excess thiol groups.
[0115] (5) The reaction mixture was purified using a desalting column (Type: 40K, 0.5 mL, REF: 87766, Lot # SJ251704, Manufacturer: Thermo).
[0116] As a control, the reaction was carried out in the presence of 0.06 mM TCEP but without ZnCl2 by the same procedure.
[0117] Homogeneity was determined. Drug / antibody ratio (DAR) and product distribution were analyzed using HIC-HPLC. Purification of D0, D1, D2, D3 and D4 was performed by hydrophobic interaction chromatography (HIC) on Tosoh TSKgel Butyl-NPR 4.6 mm ID×3.5 cm, 2.5 μm at a flow rate of 0.6 mL / min at ambient temperature. The injection volume was 50 μg, and solvent A was 1.5 M (NH4)2SO4 and 50 mM sodium phosphate pH 7. Solvent B was 75% v / v 50 mM sodium phosphate pH 7 and 25% v / v isopropanol. Different drug-loaded materials were eluted by sequential step gradients. The results are shown in Tables 3 and Figure 5-8 middle. Figure 5 is the HIC of the Rituxan-DBM-MMAF conjugate prepared by the method of the present invention, Figure 6 is a HIC of Rituxan-DBM-MMAF conjugate prepared by using conventional methods. Figure 7 is the HIC of the Erbitux-DBM-MMAF conjugate prepared by the method of the present invention, Figure 8 is a HIC of Erbitux-DBM-MMAF conjugate prepared by using conventional methods.
[0118] Table 3
[0119]
[0120] It can be seen from the test results in the above Examples 1-2 that, as shown in Tables 1, 3 and Figure 1 , 5 As shown in Figures 1 and 7, the results show that the content of D2 is usually more than 60wt%, for example more than 70wt% ( Figure 1 , 5 and 7). In contrast, the D2 content in ADCs prepared by the control conjugation method in the absence of transition metal ions was generally less than 40 wt% ( Figure 2 , 6 and 8), and the corresponding chromatograms also show that in the absence of transition metal ions, the D2 product obtained is a mixture of multiple reaction sites.
[0121] From Table 2 and Figure 3-4 It can also be seen that although Herceptin-DBM-MMAF prepared by conventional methods has similar DAR values to Herceptin-MMAF prepared by the method of the present invention, the distribution of the drugs attached to it on a single antibody is random and lacks homogeneity. The distribution of the drugs on the antibody of the product prepared by the present method has a high degree of homogeneity.
[0122] The above test results clearly show that the ADC prepared by the method of the present invention using transition metal ions has significantly improved homogeneity, which is reflected in the homogeneity of the product DAR value and the homogeneity of the drug distribution on the antibody.
[0123] Example 3 Preparation of diBrPD-VC-MMAE conjugate of antibody and homogeneity detection of the conjugate
[0124] In order to further illustrate that the method of the present invention is not only universal for coupling with a variety of proteins, but also effective for a variety of bridge linkers, this example selected another bridge linker - drug diBrPD-VC-MMAE, and applied this method to prepare a conjugate.
[0125] The diBrPD-VC-MMAE conjugate of the antibody was prepared in a one-pot reaction, and the specific steps are as follows:
[0126] (1) ZnCl2 (0.12 mM) and TCEP (0.105 mM) were added to a solution of Herceptin / Rituxan / Erbitux (prepared by WuXi Biologics according to the published corresponding protein sequences by standard methods for preparing monoclonal antibodies, 0.03 mM, in phosphate buffer, pH 7, 20 mM) and the reaction mixture was allowed to stand at 12°C overnight.
[0127] (2) diBrPD-VC-MMAE (commercially available from SyntaBio., 0.45 mM) in DMA (dimethylacetamide, commercially available from Aldrich Sigma) and EDTA (0.09 mM) were introduced to capture part of the zinc ions and the reaction was continued at 12°C for 24 hours.
[0128] (3) N-acetylcysteine (0.24 mM) was added to deplete excess diBrPD-VC-MMAE.
[0129] (4) Add EDTA (0.24 mM) to completely capture Zn 2+ And DHAA (commercially available from Aldrich Sigma, 0.24 mM) was added to oxidize excess thiol groups.
[0130] (5) The reaction mixture was purified using a desalting column (Type: 40K, 0.5 mL, REF: 87766, Lot # SJ251704, Manufacturer: Thermo).
[0131] Homogeneity was determined. Drug / antibody ratio (DAR) and product distribution were analyzed using HIC-HPLC. Purification of D0, D1, D2, D3 and D4 was performed by hydrophobic interaction chromatography (HIC) on Tosoh TSKgel Butyl-NPR 4.6 mm ID×3.5 cm, 2.5 μm at a flow rate of 0.6 mL / min at ambient temperature. The injection volume was 30 μg, and solvent A was 1.5 M (NH4)2SO4 and 50 mM sodium phosphate pH 7. Solvent B was 75% v / v 50 mM sodium phosphate pH 7 and 25% v / v isopropanol. Different drug-loaded materials were eluted by sequential step gradients. The results are shown in Tables 4 and Figure 9-11 middle, Fig. 9 is the HIC of the Herceptin-diBrPD-VC-MMAE conjugate prepared by the method of the present invention, Fig.10 is the HIC of the Rituxan-diBrPD-VC-MMAE conjugate prepared by the method of the present invention, Fig.11 is the HIC of Erbitux-diBrPD-VC-MMAF conjugate prepared by the method of the present invention.
[0132] Table 4
[0133]
[0134]
[0135] As can be seen from Table 4, by using the method of the present invention, the content of the D2 component of the antibody diBrPD-VC-MMAE conjugate can be effectively controlled to be above 60% without making major changes to the reaction process.
[0136] Example 4 Preparation of antibody-bismaleimide-VC-MMAE conjugate and homogeneity detection of the conjugate
[0137] In addition to the above examples, in order to further prove the universality of this patent, this example selects another linker-drug: Bismaleimide-VC-MMAE to prove the universality of this method. It should be noted that maleimide is the most widely used drug linker in the field of antibody-drug conjugates. The Bismaleimide molecule carries two maleimide linkers to achieve the bridging function and can undoubtedly be applied to the widest range of bridging needs.
[0138] The antibody-bismaleimide-VC-MMAE conjugate was prepared by a one-pot reaction, and the specific steps are as follows:
[0139] (1) ZnCl2 (0.12 mM) and TCEP (0.105 mM) were added to a solution of Herceptin / Rituxan / Erbitux (prepared by WuXi Biologics according to the published corresponding protein sequences by standard methods for preparing monoclonal antibodies, 0.03 mM, in phosphate buffer, pH 7, 20 mM) and the reaction mixture was allowed to stand at 12°C overnight.
[0140] (2) Bismaleimide-VC-MMAE (commercially available from Quanta Biodesign, 0.45 mM) in DMA (dimethylacetamide, commercially available from Aldrich Sigma) was introduced, and the reaction was continued at 12°C for 24 hours.
[0141] (3) N-acetylcysteine (0.24 mM) was added to deplete excess Bismaleimide-VC-MMAE.
[0142] (4) Add EDTA (0.24 mM) to capture Zn 2+ And DHAA (commercially available from Aldrich Sigma, 0.24 mM) was added to oxidize excess thiol groups.
[0143] (5) The reaction mixture was purified using a desalting column (Type: 40K, 0.5 mL, REF: 87766, Lot # SJ251704, Manufacturer: Thermo).
[0144] Homogeneity was determined. Drug / antibody ratio (DAR) and product distribution were analyzed using HIC-HPLC. Purification of D0, D1, D2, D3 and D4 was performed by hydrophobic interaction chromatography (HIC) on Tosoh TSKgel Butyl-NPR 4.6 mm ID×3.5 cm, 2.5 μm at a flow rate of 0.6 mL / min at ambient temperature. The injection volume was 30 μg, and solvent A was 1.5 M (NH4)2SO4 and 50 mM sodium phosphate pH 7. Solvent B was 75% v / v 50 mM sodium phosphate pH 7 and 25% v / v isopropanol. Different drug-loaded materials were eluted by sequential step gradients. The results are shown in Tables 5 and Figure 12-14 middle, Fig.12 is a HIC of a Herceptin-bismaleimide-VC-MMAE conjugate prepared by the method of the present invention, Fig.13 is a HIC of a Rituxan-bismaleimide-VC-MMAE conjugate prepared by using the method of the present invention, Fig.14is the HIC of Erbitux-bismaleimide-VC-MMAE conjugate prepared by using the method of the present invention.
[0145] Table 5
[0146]
[0147] As can be seen from Table 5, the method of the present invention is still applicable to bismaleimide-VC-MMAE developed based on maleimide, which is the most commonly used maleimide in the art. This proves that the method of the present invention only requires the selection of conjugated drugs to have sulfhydryl reaction activity, and is not limited to the reaction type and the type of functional group of the linker.
[0148] In summary, the present invention has developed a new bioconjugation method, which selectively modifies two drug molecules on the Fab region of the antibody using any given reactive linker without modifying the antibody sequence. The method can produce an improved, homogeneous ADC, and the operation steps are simple, which can reduce costs and increase efficiency. In the present invention, the antibody-drug 1:2 conjugate accounts for more than 60%wt% of the total components of the product. By using the method for producing an antibody-drug conjugate of the present invention, the homogeneity of the antibody-drug conjugate is higher than that of the product produced by the conventional conjugation method.
[0149] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. A method for preparing an antibody-drug conjugate DAR2 with improved homogeneity, characterized in that: The preparation method comprises: (1) incubating a reducing agent and an antibody to be conjugated in a buffer system containing transition metal ions to reduce interchain disulfide bonds within the antibody to generate reduced thiol groups; (2) covalently coupling a drug-linker complex having at least two reactive groups to the reduced thiol group obtained in step (1); thereby preparing an antibody-drug conjugate mixture; In step (2), the linker portion of the linker in the complex that is coupled to the antibody contains at least two reactive groups that are covalently coupled to two thiol groups on the antibody, respectively; In step (1), the transition metal ion is Zn 2+ ; In step (2), the reactive groups in the complex are independently selected from the group consisting of: maleimide, organic bromide, iodide, sulfone compounds, or a combination of at least two of olefin and alkyne compounds with electron-deficient groups; In step (2), the covalent coupling condition is: the molar concentration of the drug in the covalent coupling system is at least 2 times or more greater than the antibody concentration.
2. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to claim 1, characterized in that: In step (1), the reducing agent is selected from the group consisting of: tri(2-carboxyethyl)phosphine, diphenylphosphinoacetic acid, 2-[2-(diphenylphosphino)ethyl]pyridine, 3-(diphenylphosphino)benzenesulfonic acid, 4-(diphenylphosphino)benzoic acid, 2-(diphenylphosphino)ethylamine, 3-(diphenylphosphino)propylamine, 3-(diphenylphosphino)propionic acid, 2-(diisopropylphosphino)ethylamine, 2-(diphenylphosphino)benzoic acid, (2-hydroxyphenyl)diphenylphosphine, 1,3,5-triaza-7-phosphatricyclo[3.3.1.13.7]decane, n-butyldi(1-adamantyl)phosphine, sodium triacetoxyborohydride or sodium cyanoborohydride, or a combination of at least two thereof; In step (1), the final concentration of the reducing agent in the incubation system is 0.04-0.4 mM.
3. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to claim 1, characterized in that: In step (1), the transition metal ion is added to the buffer system in the form of a transition metal salt, and the transition metal salt is selected from: any one or a combination of at least two of ZnCl2, Zn(NO3)2, ZnSO4, Zn(CH3COO)2, ZnI2, ZnBr2, Zn(HCOO)2 or Zn(BF4)2; In step (1), the final concentration of the transition metal ion in the incubation system is 0.01-0.2 mM.
4. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to claim 1, characterized in that: In step (1), the buffer system is selected from: any one or a combination of at least two of HEPES buffer, histidine buffer, PBS buffer or MES buffer; In step (1), the pH of the buffer system is 5.5-7.
5.
5. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to claim 1, characterized in that: In step (1), the incubation temperature is 0°C to 20°C; In step (1), the incubation time is 8-24 hours.
6. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to claim 1, characterized in that: In step (2), the drug in the complex has cytotoxic, anti-tumor or labeling effects; In step (2), the reaction temperature is -10°C to 37°C, and the reaction time is 0.5 to 24 hours; The reaction temperature is 0°C to 20°C; The covalent coupling system further comprises an organic solvent, and the organic solvent keeps the system clear; The covalent coupling system further comprises a metal chelator, which regulates the reactivity of the drug; The metal chelating agent includes any one of EDTA, DPTA or DOTA or a combination of at least two thereof; The concentration of the metal chelator is 0-3 times the concentration of the antibody.
7. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to any one of claims 1 to 6, characterized in that: The method further comprises the step of reoxidizing the unreacted thiol groups in step (2) using an oxidizing agent; The oxidant is selected from: any one or a combination of at least two of dehydroascorbic acid, 5,5-dithiobis(2-nitrobenzoic acid), oxygen or air; The final concentration of the oxidant is 0.04-0.8 mM; The reaction conditions of the oxidation are: the concentration of the oxidant is at least higher than the concentration of the antibody, the temperature is 0°C to 20°C, and the reaction time is 0.5-24 hours.
8. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to claim 7, characterized in that: After step (2), a purification step is also included, wherein the purification step includes: using EDTA as a chelating agent to remove transition metal ions; The purification method comprises: using any one of a desalting column, size exclusion chromatography, hydrophobic interaction chromatography, an ultrafiltration tube or a tangential flow filtration system or a combination of at least two thereof for purification.
9. The method for preparing an antibody-drug conjugate DAR2 with improved homogeneity according to claim 8, characterized in that: The preparation method comprises: (1) Containing Zn 2+ A transition metal salt of a transition metal ion of is added to a buffer system, wherein the buffer system is selected from any one of a HEPES buffer, a histidine buffer, a PBS buffer or a MES buffer or a combination of at least two thereof, and the pH of the buffer system is 5-8; the reducing agent and the antibody to be conjugated are incubated at -10°C to 37°C for 8-24 hours in the buffer system containing the transition metal ion to selectively reduce the intrachain disulfide bonds of the antibody to generate reduced thiol groups; the final concentration of the reducing agent in the incubation system is 0.04-0.4 mM, and the final concentration of the transition metal ion in the incubation system is 0.01-0.2 mM; (2) covalently combining a drug having cytotoxic, anti-tumor or labeling effects with a linker containing at least two reactive groups to obtain a drug-linker complex carrying at least two reactive groups; the two reactive groups in the linker are covalently coupled to two thiol groups on the antibody respectively; covalently coupling an excess of the drug-linker complex carrying at least two reactive groups with the reduced thiol groups obtained in step (1); the conditions for the covalent coupling are: the molar concentration of the drug in the covalent coupling system is at least 2 times or more of the antibody concentration, the reaction temperature is -10°C to 37°C, and the reaction time is 0.5-24 hours; An oxidant is used to reoxidize unreacted thiol groups, and the final concentration of the oxidant is 0.04-0.8 mM; the reaction conditions of the oxidation are: the concentration of the oxidant is at least higher than the concentration of the antibody, the temperature is: -10°C to 37°C; the reaction time is 0.5-24 hours; and the antibody-drug conjugate is recovered by purifying using any one or a combination of at least two of a desalting column, size exclusion chromatography, hydrophobic interaction chromatography, ultrafiltration tube or tangential flow filtration system.
10. Use of the preparation method for improving the homogeneity of DAR2 of an antibody-drug conjugate according to any one of claims 1 to 9 in the preparation of ADC drugs.
